Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm's Series of Globalization Activities in Shanghai
SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the 2025 International Pharmaceutical Cooperation High-End Forum, one of the Kexing Biopharm's series of globalization activities in Shanghai. Themed on "Innovation for the World, Exploring for the Future," the event facilitated in-depth industry dialogues with global customers and partners, earning unanimous acclaim from attendees worldwide.
During the forum, Kexing Biopharm extended a warm welcome and heartfelt gratitude to distinguished guests and overseas customers from 20 countries, including Brazil, Colombia, Saudi Arabia, and Indonesia. Kexing Biopharm briefly introduced its recent developments, highlighting its strategic initiatives, core strengths in R&D, production, and sales, as well as its plans for overseas commercialization and development. Kexing Biopharm stated that the company's global expansion platform will remain open for collaboration, partnering with outstanding Chinese pharmaceutical and medical device enterprises to deliver superior drugs and better solutions for patients and healthcare professionals worldwide. The company is advancing rapidly toward its strategic goal of internationalization.
Additionally, multiple overseas partners delivered keynote speeches at the forum. Experts from Brazil's GGFIS and ANVISA presented insights into Brazil's regulatory policy system. Senior executives from partner organizations in Brazil, Saudi Arabia, Indonesia, and Vietnam elaborated on their local pharmaceutical development landscapes, respectively. They highlighted the characteristics of distribution channels, medication needs, market access, and pharmaceutical localization strategies, offering attendees valuable perspectives on international markets.
Moreover, during the CPHI China 2025 from June 24 to 26, Kexing Biopharm was invited to participate in multiple professional forums on pharmaceutical overseas commercialization. It engaged with Chinese innovative pharmaceutical enterprises, industry leaders, and cooperative customers to explore new opportunities for the global expansion of pharmaceutical enterprises. At its exhibition booth, Kexing Biopharm showcased over 20 high-quality pharmaceutical products, synthetic biology solutions, and medical aesthetic offerings. The company also discussed its innovative drug pipelines in development and overseas commercialization strategies with both existing and potential customers, laying a solid foundation for future collaboration and mutual success.
Amid the profound restructuring of the global pharmaceutical industry chain, Kexing Biopharm's international platform will remain innovation-driven and cooperation-oriented, delivering high-quality drugs worldwide. The company will continue to empower more Chinese pharmaceutical enterprises to enter global markets, thereby safeguarding patients across the globe.